Cargando…

Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis

The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chukwudozie, Onyeka S., Chukwuanukwu, Rebecca C., Iroanya, Onyekachi O., Eze, Daniel M., Duru, Vincent C., Dele-Alimi, Temiloluwa O., Kehinde, Busuyi D., Bankole, Taiwo T., Obi, Perpetua C., Okinedo, Elizabeth U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501546/
https://www.ncbi.nlm.nih.gov/pubmed/32964056
http://dx.doi.org/10.1155/2020/2837670
_version_ 1783584049568153600
author Chukwudozie, Onyeka S.
Chukwuanukwu, Rebecca C.
Iroanya, Onyekachi O.
Eze, Daniel M.
Duru, Vincent C.
Dele-Alimi, Temiloluwa O.
Kehinde, Busuyi D.
Bankole, Taiwo T.
Obi, Perpetua C.
Okinedo, Elizabeth U.
author_facet Chukwudozie, Onyeka S.
Chukwuanukwu, Rebecca C.
Iroanya, Onyekachi O.
Eze, Daniel M.
Duru, Vincent C.
Dele-Alimi, Temiloluwa O.
Kehinde, Busuyi D.
Bankole, Taiwo T.
Obi, Perpetua C.
Okinedo, Elizabeth U.
author_sort Chukwudozie, Onyeka S.
collection PubMed
description The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of the nucleocapsid protein that aid in viral replication. Promising antigenic B cell and T cell epitopes were predicted using computational pipelines. The peptides “RIRGGDGKMKDL” and “AFGRRGPEQTQGNFG” were the B cell linear epitopes with good antigenic index and nonallergenic property. Two CD8(+) and Three CD4(+) T cell epitopes were also selected considering their safe immunogenic profiling such as allergenicity, antigen level conservancy, antigenicity, peptide toxicity, and putative restrictions to a number of MHC-I and MHC-II alleles. With these selected epitopes, a nonallergenic chimeric peptide vaccine incapable of inducing a type II hypersensitivity reaction was constructed. The molecular interaction between the Toll-like receptor-5 (TLR5) which was triggered by the vaccine was analyzed by molecular docking and scrutinized using dynamics simulation. Finally, in silico cloning was performed to ensure the expression and translation efficiency of the vaccine, utilizing the pET-28a vector. This research, therefore, provides a guide for experimental investigation and validation.
format Online
Article
Text
id pubmed-7501546
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-75015462020-09-21 Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis Chukwudozie, Onyeka S. Chukwuanukwu, Rebecca C. Iroanya, Onyekachi O. Eze, Daniel M. Duru, Vincent C. Dele-Alimi, Temiloluwa O. Kehinde, Busuyi D. Bankole, Taiwo T. Obi, Perpetua C. Okinedo, Elizabeth U. J Immunol Res Research Article The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of the nucleocapsid protein that aid in viral replication. Promising antigenic B cell and T cell epitopes were predicted using computational pipelines. The peptides “RIRGGDGKMKDL” and “AFGRRGPEQTQGNFG” were the B cell linear epitopes with good antigenic index and nonallergenic property. Two CD8(+) and Three CD4(+) T cell epitopes were also selected considering their safe immunogenic profiling such as allergenicity, antigen level conservancy, antigenicity, peptide toxicity, and putative restrictions to a number of MHC-I and MHC-II alleles. With these selected epitopes, a nonallergenic chimeric peptide vaccine incapable of inducing a type II hypersensitivity reaction was constructed. The molecular interaction between the Toll-like receptor-5 (TLR5) which was triggered by the vaccine was analyzed by molecular docking and scrutinized using dynamics simulation. Finally, in silico cloning was performed to ensure the expression and translation efficiency of the vaccine, utilizing the pET-28a vector. This research, therefore, provides a guide for experimental investigation and validation. Hindawi 2020-09-17 /pmc/articles/PMC7501546/ /pubmed/32964056 http://dx.doi.org/10.1155/2020/2837670 Text en Copyright © 2020 Onyeka S. Chukwudozie et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chukwudozie, Onyeka S.
Chukwuanukwu, Rebecca C.
Iroanya, Onyekachi O.
Eze, Daniel M.
Duru, Vincent C.
Dele-Alimi, Temiloluwa O.
Kehinde, Busuyi D.
Bankole, Taiwo T.
Obi, Perpetua C.
Okinedo, Elizabeth U.
Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
title Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
title_full Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
title_fullStr Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
title_full_unstemmed Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
title_short Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
title_sort attenuated subcomponent vaccine design targeting the sars-cov-2 nucleocapsid phosphoprotein rna binding domain: in silico analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501546/
https://www.ncbi.nlm.nih.gov/pubmed/32964056
http://dx.doi.org/10.1155/2020/2837670
work_keys_str_mv AT chukwudozieonyekas attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT chukwuanukwurebeccac attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT iroanyaonyekachio attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT ezedanielm attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT duruvincentc attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT delealimitemiloluwao attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT kehindebusuyid attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT bankoletaiwot attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT obiperpetuac attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis
AT okinedoelizabethu attenuatedsubcomponentvaccinedesigntargetingthesarscov2nucleocapsidphosphoproteinrnabindingdomaininsilicoanalysis